OR4D9

Across TCGA pan-cancer cohorts, OR4D9 RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated OR4D9 data layer compared with 3 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR4D9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR4D9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and ESCA show a favorable association.

LIHC, BRCA, and LAML are the cancer types where OR4D9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.433	0.783	<.001	72	view →
BRCA	DFS	Tertile	IV	0.175	0.730	.005	36	view →
LAML	DFS	Tertile	All	0.028	0.583	.001	36	view →
STAD	DFS	Tertile	IV	0.097	0.412	.008	30	view →
THCA	DFS	Tertile	II,III,IV	0.622	0.927	.013	18	view →
SARC	OS	Tertile	All	0.109	0.827	<.001	18	view →
HNSC	OS	Tertile	II,III,IV	0.756	0.331	.021	15	view →
ESCA	OS	Quartile	III,IV	0.757	0.350	.032	13	view →
OV	DFS	Tertile	IV	1.000	0.433	.033	6	view →
LGG	DFS	Tertile	All	0.472	0.763	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

OR4D9–LIHC (OS)

Open the LIHC breakdown →